Company Monitoring Page for Roche

latest headlines for company on cafepharma

AstraZeneca's Alexion hopes to extend dominance in PNH as Big Pharma competitors close in
Fierce Biotech
Fri, 12/16/22 - 10:47 am
Tags:
AstraZeneca, Alexion, PNH, Ultomiris, Soliris, Roche, Apellis, Novartis
Roche wins earlier-than-expected approval for blockbuster Tecentriq in rare soft tissue cancer
Endpoints
Tue, 12/13/22 - 11:50 pm
Tags:
Roche, Tecentriq, FDA, soft tissue cancer
ASH: Roche records phase 3 rare disease win ahead of Soliris showdown
Fierce Biotech
Mon, 12/12/22 - 10:29 am
Tags:
ASH 2022, Roche, PNH, crovalimab, AstraZeneca, Soliris
After 16 Years, Roche's Pharma Division Head Decides To Step Down
Yahoo/Benzinga
Mon, 12/12/22 - 10:24 am
Tags:
Roche, Bill Anderson
ASH: Roche touts Lunsumio's durable efficacy as AbbVie, Regeneron plot lymphoma bispecific battle
Fierce Pharma
Mon, 12/12/22 - 10:21 am
Tags:
Roche, ASH 2022, AbbVie, Regeneron, lymphoma, Lunsumio, glofitamab
Combo of Roche's Tecentriq and Exelixis' Cabometyx fails another trial, this time in lung cancer
Fierce Pharma
Sun, 12/11/22 - 01:20 pm
Tags:
Roche, Tecentriq, Exelixis, Cabometyx, clinical trials, non small cell lung cancer
SABCS: AZ writes the 'next chapter' in Enhertu's saga with head-to-head win versus Roche's Kadcyla
Fierce Pharma
Fri, 12/9/22 - 10:54 am
Tags:
SABCS, AstraZeneca, Enhertu, breast cancer, Daiichi Sankyo, Roche, Kadcyla
Roche, having shared data with regulators, unwraps results of subcutaneous Tecentriq phase 3 trial
Fierce Pharma
Thu, 12/1/22 - 10:55 am
Tags:
Roche, Tecentriq, clinical trials, non-small cell lung cancer
CTAD 2022 – gantenerumab’s shortcomings keep amyloid hypothesis alive
EP Vantage
Thu, 12/1/22 - 10:28 am
Tags:
Roche, clinical trials, CTAD, Alzheimer's disease, gantenerumab
Go or no go? Mirati heads to the FDA
EP Vantage
Wed, 11/30/22 - 10:34 am
Tags:
FDA, Mirati Therapeutics, Gilead Sciences, Coherus Biosciences, Roche, Biogen, TG Therapeutics, Ipsen, Novartis, BeiGene, Cytokinetics
Roche Withdraws Tecentric for Bladder Cancer Indication
BioSpace
Tue, 11/29/22 - 11:06 am
Tags:
Roche, Genentech, bladder cancer, metastatic bladder cancer, Tecentriq
FogPharma’s $178M Funding Leads Way as 7 Biotechs Raise Cash for Cancer Drugs
MedCity News
Sun, 11/27/22 - 07:04 pm
Tags:
FogPharma, funding, cancer, CatalYm, Roche, Opna Bio, Rezo Therapeutics
Despite high demand, Tamiflu drugmaker says it's on track with supply
Beckers Hospital Review
Mon, 11/21/22 - 07:18 pm
Tags:
Tamiflu, Flu, Roche
AbbVie's Roche-rivaling blood cancer bispecific gets FDA priority review, triggering Genmab payday
Fierce Biotech
Mon, 11/21/22 - 10:12 am
Tags:
AbbVie, Genmab, FDA, Roche, epcoritamab, bispecific antibodies, relapsed or refractory large B-cell lymphoma
Roche Failure Leaves Industry Reassessing Alzheimer's Space
BioSpace
Wed, 11/16/22 - 10:45 am
Tags:
Roche, Alzheimer's disease, gantenerumab, Biogen, Cassava Sciences, Eli Lilly
Roche Doubles Down on Jnana's RAPID Platform in $2B Deal (Updated)
BioSpace
Wed, 11/16/22 - 10:13 am
Tags:
Roche, Jnana Therapeutics, small molecule drugs, drug development
After $250M Roche buyout, a startup plans a second strike with fresh funding
BioPharma Dive
Tue, 11/15/22 - 10:36 am
Tags:
Bonum Therapeutics, startups, Roche, Good Therapeutics, funding
Trial failures end latest hope for Roche’s Alzheimer’s drug
BioPharma Dive
Mon, 11/14/22 - 10:57 am
Tags:
Roche, Alzheimer's disease, gantenerumab, clinical trials
As Roche prepares to take a kidney disease drug into PhIII, Ionis fleshes out the data
Endpoints
Mon, 11/7/22 - 05:24 pm
Tags:
Roche, Ionis Pharmaceuticals, IONIS-FB-LRx, kidney disease
Roche introduces the navify brand for its digital health solutions at HLTH 2022
BioSpace
Fri, 11/4/22 - 11:05 am
Tags:
Roche, navify, digital health, software, digital pharma

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.